Publications by authors named "Wen-Lu Tang"
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Cochrane Database Syst Rev
October 2020
Background: Renin inhibitors (RIs) reduce blood pressure more than placebo, with the magnitude of this effect thought to be similar to that for angiotensin converting enzyme (ACE) inhibitors. However, a drug's efficacy in lowering blood pressure cannot be considered as a definitive indicator of its effectiveness in reducing mortality and morbidity. The effectiveness and safety of RIs compared to ACE inhibitors in treating hypertension is unknown.
View Article and Find Full Text PDFBackground: This is the first update of a Cochrane Review first published in 2015. Renin angiotensin system (RAS) inhibitors include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and renin inhibitors. They are widely prescribed for treatment of hypertension, especially for people with diabetes because of postulated advantages for reducing diabetic nephropathy and cardiovascular morbidity and mortality.
View Article and Find Full Text PDFBackground: Renin-angiotensin system (RAS) inhibitors are widely prescribed for treatment of hypertension, especially for diabetic patients on the basis of postulated advantages for the reduction of diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for hypertension in both diabetic and non-diabetic patients, the efficacy and safety of RAS inhibitors compared to other antihypertensive drug classes remains unclear.
Objectives: To evaluate the benefits and harms of first-line RAS inhibitors compared to other first-line antihypertensive drugs in patients with hypertension.
Study of the process of secondary failure of sulphonylurea by a Markov model.
Pharmacoepidemiol Drug Saf
May 2008
Article Synopsis
- * Data was collected from 549 patients through door-to-door surveys, and the Markov model helped assess the SFS process and its influencing factors.
- * Results showed varying rates of SFS among different patient groups and indicated that higher pre-treatment glucose levels led to faster development of SFS, suggesting that simply switching sulphonylurea types won't delay this progression.
Article Synopsis
- The study examined how the combination of norfloxacin and biphenylacetic acid affects IL-1beta levels in the brains of rats, particularly in relation to seizure activity.
- Rats experienced clonic convulsions when given norfloxacin together with biphenylacetic acid, with EEG monitoring showing clear seizure patterns.
- Results indicated that this combination transiently increased IL-1beta mRNA and protein in the prefrontal cortex and hippocampus, suggesting these regions are crucial in mediating seizures triggered by norfloxacin.
Aim: To observe the effects of stearic acid, a long-chain saturated fatty acid consisting of 18 carbon atoms, on brain (cortical or hippocampal) slices insulted by oxygen-glucose deprivation (OGD), glutamate or sodium azide (NaN3) in vitro.
Methods: The activities of hippocampal slices were monitored by population spikes recorded in the CA1 region. In vitro injury models of brain slice were induced by 10 min of OGD, 1 mmol/L glutamate or 10 mmol/L NaN3.
Assessment of quality of life and relevant factors in elderly diabetic patients in the Shanghai community.
Pharmacoepidemiol Drug Saf
February 2006
Purpose: The study was to assess the quality of life (QOL) of the elderly diabetes mellitus (DM) in Shanghai community and to screen the possible risk factors.
Methods: A total of 951 patients with elderly DM and 1007 elderly subjects with normal glucose tolerance from the same community as control group were enrolled in the study. A door-to-door retrospectively epidemiological survey was used to collect data of QOL, demographic, and diabetic information.